Domiphen Bromide
CAS 538-71-6
Domiphen Bromide (CAS 538-71-6) is a Phase 2 pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 30057.51481481481 nM | 81 | - |
| - | IC50 | 16712.135000000002 nM | 4 | - |
| - | AC50 | 34913.43333333333 nM | 3 | - |
| - | IC50 | 33 ug.mL-1 | 1 | - |
| - | MIC | 40820 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Domiphen Bromide used for in pharmaceutical contexts?
Domiphen Bromide (CAS 538-71-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Domiphen Bromide?
No adverse-event association or SIDER side-effect rows are rendered for Domiphen Bromide in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Domiphen Bromide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Domiphen Bromide with EU status "restricted".
What clinical phase is Domiphen Bromide in?
Domiphen Bromide is rendered with ChEMBL max phase 2.